Literature DB >> 22515389

Exacerbations of severe asthma.

V M McDonald1, P G Gibson.   

Abstract

Exacerbations occur frequently in severe asthma. They result in significant morbidity and can lead to hospitalization and death. Severe exacerbations can also lead to an accelerated decline in lung function. Phenotyping severe asthma can aid with both prognostication of exacerbation risk and maintenance treatment selection to minimize future risks of exacerbations in severe asthma. The rate of exacerbations differs by phenotype, and is most frequent in refractory eosinophilic asthma and early onset allergic asthma. Phenotype specific therapy can reduce exacerbations in both these forms of severe asthma. Exacerbations are multi-component events. Each exacerbation represents an opportunity to assess and target treatment to the domains of airway pharmacotherapy, self-management behaviour, risk factors, and relevant co-morbidities.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22515389     DOI: 10.1111/j.1365-2222.2012.03981.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  13 in total

1.  Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia.

Authors:  Bo Liu; Jee-Boong Lee; Chun-Yu Chen; Gurjit K Khurana Hershey; Yui-Hsi Wang
Journal:  J Immunol       Date:  2015-03-16       Impact factor: 5.422

2.  Tumstatin regulates the angiogenic and inflammatory potential of airway smooth muscle extracellular matrix.

Authors:  Louise Margaret Harkness; Markus Weckmann; Matthias Kopp; Tim Becker; Anthony Wayne Ashton; Janette Kay Burgess
Journal:  J Cell Mol Med       Date:  2017-06-13       Impact factor: 5.310

Review 3.  Late-onset asthma: current perspectives.

Authors:  Tsunahiko Hirano; Kazuto Matsunaga
Journal:  J Asthma Allergy       Date:  2018-02-09

4.  Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease.

Authors:  Katherine J Baines; Juan-Juan Fu; Vanessa M McDonald; Peter G Gibson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-02-08

Review 5.  Treatable traits in acute exacerbations of chronic airway diseases.

Authors:  Vanessa M McDonald; Christian R Osadnik; Peter G Gibson
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

6.  Plasminogen activator inhibitor-1 in sputum and nasal lavage fluids increases in asthmatic patients during common colds.

Authors:  Seong H Cho; Seung J Hong; Haimei Chen; Ali Habib; David Cho; Sun H Lee; Joseph Kang; Theresa Ward; Homer A Boushey; Robert P Schleimer; Pedro C Avila
Journal:  J Allergy Clin Immunol       Date:  2013-12-24       Impact factor: 10.793

7.  Vitronectin expression in the airways of subjects with asthma and chronic obstructive pulmonary disease.

Authors:  Lina M Salazar-Peláez; Thomas Abraham; Ana M Herrera; Mario A Correa; Jorge E Ortega; Peter D Paré; Chun Y Seow
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

Review 8.  Distinguishing adult-onset asthma from COPD: a review and a new approach.

Authors:  Michael J Abramson; Jennifer L Perret; Shyamali C Dharmage; Vanessa M McDonald; Christine F McDonald
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-09

9.  Identifying Asthma Exacerbation-Related Emergency Department Visit Using Electronic Medical Record and Claims Data.

Authors:  Agnes S Sundaresan; Gargi Schneider; Joy Reynolds; H Lester Kirchner
Journal:  Appl Clin Inform       Date:  2018-07-18       Impact factor: 2.342

10.  Treatment, outcomes and costs of asthma exacerbations in Chilean children: a prospective multicenter observational study.

Authors:  A M Herrera; P Brand; G Cavada; A Koppmann; M Rivas; J Mackenney; H Sepúlveda; M E Wevar; L Cruzat; S Soto; M A Pérez; A León; I Contreras; C Alvarez; B Walker; C Flores; V Lezana; C Garrido; M E Herrera; A Rojas; C Andrades; E Chala; R A Martínez; M Vega; J A Perillán; H Seguel; I Przybyzsweski
Journal:  Allergol Immunopathol (Madr)       Date:  2018-12-27       Impact factor: 1.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.